Tejnaksh Healthcare Reports FY26 Profit Decline, Cancels Rights Issue

Consolidated profit after tax for FY26 stood at ₹1.18 crore, a 47% drop from ₹2.23 crore in FY25. Consolidated total income fell to ₹11.18 crore from ₹13.30 crore.

Reader Takeaway: Declining financials and cancelled rights issue signal a pause in growth strategy.

What just happened

Tejnaksh Healthcare Limited has announced its audited financial results for the fiscal year ended March 31, 2026. The company reported a decline in both total income and profit after tax on both consolidated and standalone bases compared to the previous fiscal year.

Furthermore, the Board of Directors has decided to cancel the proposed Rights Issue. This decision is attributed to the postponement of the company's expansion plans.

Why this matters

For investors, the declining financial performance indicates potential challenges in revenue generation or cost management. The cancellation of the rights issue, directly linked to paused expansion, suggests a more conservative near-term outlook for growth. This might impact future earnings potential and stock valuation.

The backstory

In the previous fiscal year, FY25, Tejnaksh Healthcare had reported consolidated total income of ₹13.30 crore and a profit after tax of ₹2.23 crore. The standalone figures for FY25 were ₹9.15 crore and ₹2.62 crore, respectively. The company had previously announced plans for a rights issue to fund its expansion, the details of which are now superseded by the cancellation.

What changes now

The company will not be raising funds through the Rights Issue as initially planned. The focus on postponed expansion plans means that immediate capital expenditure for growth initiatives will be scaled back. The company will continue to operate within its Medical and Healthcare Services segment.

Risks to watch

Key risks include the continued downward trend in financial performance, the reasons behind the postponement of expansion plans, and the company's ability to revive growth strategies in the future. Uncertainty regarding future expansion could affect investor confidence.

Peer comparison

While specific peer financial data for FY26 is not yet fully available, the healthcare services sector in India is generally seeing growth, though individual company performances can vary widely based on operational efficiency and market positioning.

Context metrics (time-bound)

Consolidated FY26:

• Total Income: ₹11.18 crore (down from ₹13.30 crore in FY25)
• Profit After Tax: ₹1.18 crore (down from ₹2.23 crore in FY25)
• EPS: ₹0.61 (down from ₹1.15 in FY25)

Standalone FY26:

• Total Income: ₹7.55 crore (down from ₹9.15 crore in FY25)
• Profit After Tax: ₹1.38 crore (down from ₹2.62 crore in FY25)
• EPS: ₹0.68 (down from ₹1.29 in FY25)

What to track next

Investors should closely monitor management commentary regarding the revised expansion plans, future revenue growth drivers, and any updates on the company's strategic direction. The impact of the gratuity liability reversal recognized as other income also warrants attention.